|
| Home : Trillium Announces Pricing of US$30.0 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preference Shares |
|
May 27
2017 |
Trillium Announces Pricing of US$30.0 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preference Shares |
|
TORONTO, ONTARIO--(Marketwired - May 26, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced underwritten public offering of 2,750,000 common shares and 3,250,000 Series II Non-Voting Convertible First Preferred Shares. The common shares are being sold at a public offering price of US$5.00 per share and the Series II Non-Voting Convertible First Preferred Shares are being sold at a public offering price of US$5.00 per share. The gross proceeds to the Company from this offering are expected to be approximately US$30.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Company has also granted the underwriters a 30-day option to purchase from it up to an additional 412,500 common shares on the same terms and conditions. The offering is expected to close on June 1, 2017, subject to the satisfaction of customary closing conditions. |
|
|
|
| Source:http://www.marketwired.com/mw/release.do?id=2218714&sourceType=3 |
| |
|
Related News
|
» Nobel Biocare, Straumann, Dentsply Sirona Lead US Dental Implant Fixtures Market Despite Pricing Pressure from Low-Cost Competitors
» Genius Announces Closing of Financing and Acquisitions
|
|
|
